Creso Pharma’s (ASX: CPH) Canadian subsidiary, Mernova Medical, has begun cultivation at their Nova Scotia facility.
The approximately 2,200 square meter facility was granted a licence by Health Canada in February, and has in place three-year, 100kg flower per month minimum, supply agreement with TerrAscend Canada.
Creso has a number of high THC and CBD strains which are to be cultivated at the Mernova facility, with the first harvest expected in May.
The facility is currently holds a Canadian GMP certification, although there are intentions to obtain EU-GMP certification as well, which will allow Creso to export to Europe.
Creso’s CEO and Co-founder, Dr Miri Halperin Wernli Creso’s CEO and Co-Founder said, “We are very pleased that our subsidiary Mernova has commenced cultivation at its Nova Scotia facility so soon after receiving its license. The cannabis genetics being used there are of very high quality and the grow operation is proceeding as planned along with the certification process of EU-GMP that will allow export to pharma companies in Europe. Mernova’s partnership with TerrAscend is progressing well and we look forward to seeing the results of the first harvest from the facility.”